Condition
Natural Killer Cell Malignancies
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02722668Phase 2Completed
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT03314974Phase 2Recruiting
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT02991898Phase 2Terminated
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Showing all 3 trials